Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example

A well-coordinated interaction between extracellular signals and intracellular response forms the basis of life within multicellular organisms, with growth factors playing a crucial role in these interactions. Discoveries in recent years have shown that components of the Epidermal Growth Factor (EGF) signaling system have frequently been used by cancer cells to autonomously provide survival and proliferation signals. The main focus of this review is the ErbB epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases including ErbB1/EGFR, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4 as therapeutic targets. Since the ErbB receptor family regulates cell proliferation through the Ras-mitogen-activated protein kinase (RAS/MAPK) pathway, and cell survival and transformation through the phosphatidylinositol 3-kinase (PI3K/AKT) pathway, pharmacological targeting of these pathways is also discussed. We will also address the clinical studies that have been conducted to evaluate antibody-based therapies mostly on solid tumors and hematologic malignancies.

[1]  W. Schmiegel,et al.  Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer , 2006, British Journal of Cancer.

[2]  M. Los,et al.  Monoclonal and bispecific antibodies as novel therapeutics , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[3]  S. Maddika,et al.  The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation , 2006, Expert opinion on therapeutic targets.

[4]  L. Wolfraim.  Treating autoimmune diseases through restoration of antigen-specific immune tolerance , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[5]  S. Maddika,et al.  Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor‐positive and ‐negative human breast cancer cells via the intrinsic pathway , 2005, Cell proliferation.

[6]  S. Mai.  Telomeres, Genomic Instability, DNA Repair and Breast Cancer , 2005 .

[7]  Raphael Sandaltzopoulos,et al.  Cancer Immunotherapy: Battling Tumors with Gene Vaccines , 2005 .

[8]  M. Los,et al.  Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. , 2005, Archivum immunologiae et therapiae experimentalis.

[9]  M. Caraglia,et al.  Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors , 2005, Current opinion in oncology.

[10]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Herrmann,et al.  Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.

[12]  A. Berrebi,et al.  Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. , 2005, Molecular cancer therapeutics.

[13]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[14]  Zhen-ping Zhu,et al.  Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II. , 2004, Acta pharmacologica Sinica.

[15]  S. Knox,et al.  Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. , 2004, International journal of radiation oncology, biology, physics.

[16]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Prakash Chinnaiyan,et al.  Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.

[18]  E. Van Cutsem,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[19]  E. Vokes,et al.  Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) , 2004 .

[20]  R. Wolff,et al.  Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[22]  M. Los,et al.  Caspases and cancer: mechanisms of inactivation and new treatment modalities. , 2004, Experimental oncology.

[23]  M. Kreuter,et al.  Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. , 2004, Archivum immunologiae et therapiae experimentalis.

[24]  Nico P E Vermeulen,et al.  Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.

[25]  Louis M. Weiner,et al.  Improving monoclonal antibodies for cancer therapy , 2004 .

[26]  S. Gibson,et al.  Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. , 2004, Current cancer drug targets.

[27]  Tracy Kim.  Technology evaluation: Matuzumab, Merck KGaA. , 2004, Current opinion in molecular therapeutics.

[28]  G. Ostroff,et al.  Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. , 2003, Cancer research.

[29]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[30]  A. Zlotnik,et al.  Targeting tumor cells. , 2003, Current opinion in cell biology.

[31]  E. Surmacz.  Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor , 2003, Oncogene.

[32]  A. Dalgleish,et al.  Cancer immunotherapy: an embarrassment of riches? , 2003, Drug discovery today.

[33]  T. Waldmann,et al.  Immunotherapy: past, present and future , 2003, Nature Medicine.

[34]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[35]  David A. Cheresh,et al.  Get a ligand, get a life: integrins, signaling and cell survival , 2002, Journal of Cell Science.

[36]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[38]  A. Kortt,et al.  Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. , 2001, Biomolecular engineering.

[39]  Y. Yovtchev,et al.  Opportunities for up to date treatment of the colorectal cancer , 2001 .

[40]  Louis M Weiner,et al.  New approaches to antibody therapy , 2000, Oncogene.

[41]  C. White,et al.  Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. , 2000, Current pharmaceutical biotechnology.

[42]  G. Kroemer,et al.  The mitochondrion in cell death control: certainties and incognita. , 2000, Experimental cell research.

[43]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[44]  J. Schlessinger.  New Roles for Src Kinases in Control of Cell Survival and Angiogenesis , 2000, Cell.

[45]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[46]  K. Schulze-Osthoff,et al.  The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. , 1999, Immunity.

[47]  G. Tortora,et al.  Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  K. Schulze-Osthoff,et al.  Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. , 1998, Journal of immunology.

[49]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[50]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[51]  J. Kinet,et al.  Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. , 1996, Immunity.

[52]  W. Fiers,et al.  Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis , 1995, Nature.

[53]  H. Modjtahedi,et al.  The Binding of HB-EGF to Tumor Cells Is Blocked by mAbs Which Act as EGF and TGFα Antagonists , 1995 .

[54]  P. Carter,et al.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.

[55]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[57]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[58]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[59]  T. Meyer,et al.  Role of chromosomal rearrangement in N. gonorrhoeae pilus phase variation , 1985, Cell.

[60]  C. Riggs,et al.  Dose response studies of carcinogenesis in rats by nitrosodiethylamine. , 1981, Cancer research.

[61]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[62]  P. Harari.  Promising new advances in head and neck radiotherapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  S. Gibson,et al.  Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer , 2005 .

[64]  M. Los,et al.  Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets. , 2005, Archivum immunologiae et therapiae experimentalis.

[65]  E. Vokes,et al.  Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  C. White,et al.  Antibody-targeted immunotherapy for treatment of malignancy. , 2001, Annual review of medicine.

[67]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[68]  H. Modjtahedi,et al.  The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists. , 1995, Biochemical and biophysical research communications.

[69]  Z. Wieczorek,et al.  PHAGOCYTOSIS OF ATYPICAL MYCOBACTERIA FROM VARIOUS SOURCES. , 1965, Archivum immunologiae et therapiae experimentalis.

[70]  L. Presta,et al.  Humanization of an anti-p 185 HER 2 antibody for human cancer therapy ( antibody engineering / site-directed mutagenesis / c-erbB2 / neu ) , 2022 .